Biocon Limited — Investor Meet, 30-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon Limited reported muted financial performance for Q2 FY25, with double-digit revenue growth in Biosimilars but declines in Generics and Research Services. Total revenue remained flat at ₹3,623 crore. Biocon Biologics successfully refinanced long-term debt, enhancing liquidity. The company anticipates a stronger second half of the fiscal year, driven by new product launches and recovery in Research Services. Key strategic developments include licensing agreements in emerging markets and ongoing inspections to ensure compliance with regulatory standards.